-- Cardiovascular disease is the number one cause of death globally, according to the Journal of the American College of Cardiology: Asia. Behind this statistic lies a growing health crisis, impacting families, communities, and healthcare systems alike. As the burden escalates, so does the imperative to shift from reactive, crisis-driven care to a more preventive and sustainable approach. Introducing Intermittent Hypoxia-Hyperoxia Therapy (IHHT): a science-backed, non-invasive breathing therapy that strengthens the cardiovascular system at its cellular core. By training the body to adapt to fluctuating oxygen levels, IHHT enhances heart function, improves metabolic efficiency, supports cognitive health, and reduces inflammation.
What Is IHHT?
IHHT is a therapeutic technique that cycles between controlled low-oxygen (hypoxia) and high-oxygen (hyperoxia) breathing. This “interval training for your cells” boosts the body’s resilience, improves oxygen efficiency, and supports cardiovascular, cognitive, and metabolic health.
Think of it as a workout for your lungs and mitochondria that trains your body to optimise energy use, lower inflammation, and improve performance from the inside out.
Unlike continuous hypoxia, which can be harmful, IHHT uses carefully regulated intervals to ensure both safety and effectiveness.
How It Works: The Science and Technology Behind IHHT
The underlying science of IHHT draws on over 10 years of clinical research into oxygen therapy and cellular adaptation. Its efficacy is rooted in oxygen-sensing molecular mechanisms, a discovery that won the 2019 Nobel Prize in Medicine. These mechanisms regulate gene activity in response to oxygen levels, triggering protective and regenerative processes at the cellular level.
Central to this approach is SRT-Technology (Self-Regulated Treatment), which powers devices like ReOxy® and HIBERG®. SRT-technology uses real-time data such as heart rate and blood oxygen saturation, captured via a built-in pulse oximeter to tailor the air mixture and timing for each individual.
SRT-technology enables:
· Pre-treatment testing to define the patient’s optimal therapeutic zone
· Individualized treatment adjustment based on real-time physiological responses
· Post-session analysis to calculate and store treatment parameters for future treatment plans
What the Research Shows
A 2023 review published in Metabolites (Vol. 13, Issue 181) analysed 16 clinical studies from Europe and Asia. IHHT was shown to deliver consistent benefits across cardiovascular, neurological, and metabolic domains:
Cardiac Rehabilitation (Glazachev et al., 2017)
Design: 46 CAD patients underwent 15 IHHT sessions (4–6 min hypoxia at 10–12% O₂, 3 min hyperoxia at 30–35% O₂).
Results: Significant improvements in exercise tolerance, lipid profiles, and quality of life, with no adverse effects.
Cognitive Health (Serebrovska et al., 2019)
Design: Elderly patients with mild cognitive impairment received 15 IHHT sessions.
Results: MoCA test scores (cognitive assessment) improved by 20%, linked to reduced neuroinflammation and enhanced brain oxygenation.
Metabolic Syndrome (Bestavashvili et al., 2021)
Design: 65 patients with metabolic syndrome completed 3 weeks of IHHT.
Results: Reduced LDL cholesterol, lower inflammatory markers (e.g., TNF-α), and better blood sugar control.
Geriatric Care (Bayer et al., 2017)
Design: IHHT paired with multimodal therapy in elderly patients.
Results: 30% greater improvement in mobility and cognitive function compared to standard rehab alone.
Full study:
Effectiveness of Intermittent Hypoxia–Hyperoxia Therapy in Different Pathologies with Possible Metabolic Implications https://www.mdpi.com/2218-1989/13/2/181
Adaptations following an intermittent hypoxia-hyperoxia training in coronary artery disease patients: a controlled study https://onlinelibrary.wiley.com/doi/10.1002/clc.22670
But the benefits don't stop at what's been proven—they ripple outward. Like throwing a stone into a pond, IHHT's cellular-level effects create waves of improvement across multiple systems. Researchers are now discovering that by "exercising" our oxygen metabolism, we may unlock: IHHT’s Ripple Effects.
The Ripple Effects of IHHT
1. Brain & Nervous System
20% cognitive improvement in elderly patients
Potential support for neurodegenerative disease prevention
2. Metabolism & Aging
Improved insulin sensitivity
Activation of longevity-related genes (e.g., sirtuins)
3. Performance & Recovery
Enhanced oxygen use and faster muscle recovery in athletes
4. Immunity & Inflammation
Reduction of inflammatory markers (e.g., TNF-α)
Possible modulation of autoimmune responses
From Clinical Evidence to Real-World Application: ReOxy® and HIBERG®
Once reserved for elite athletes and clinical trials, IHHT is now accessible to both medical professionals and health-conscious individuals:
ReOxy® is a CE-certified medical device designed for clinical settings. It delivers fully automated IHHT protocols tailored to individual patients, making it ideal for cardiology, rehabilitation, and integrative medicine practices.
HIBERG® adapts the same core technology for personal use, offering guided breathing sessions to support recovery, stress relief, sleep, and energy balance. It’s a powerful wellness solution for anyone seeking performance and longevity.
Both devices are powered by SRT-Technology, ensuring personalised, safe, and effective treatment every session.
IHHT: A Proactive Solution for Heart Health and Overall Wellness
In a world where heart disease is a leading cause of death, IHHT offers a proactive solution that goes beyond traditional treatments. By improving how the body uses oxygen, IHHT strengthens heart health and enhances circulation. But its benefits extend further, by supporting metabolic function, boosting cognitive clarity, and promoting overall wellness, IHHT helps nurture a healthier, more resilient body. Embrace IHHT as a powerful tool for reclaiming your heart health and enhancing your quality of life, one breath at a time. Each breath, each session brings you closer to better health.
About Ai Mediq SA
Headquartered in Luxembourg, Ai Mediq SA specializes in developing advanced breathing therapies based on controlled intermittent hypoxia and hyperoxia. With a strong foundation in R&D and clinical validation, Ai Mediq SA leads the field in adaptive respiratory technologies. Its flagship solutions, ReOxy® and HIBERG®, are cutting-edge, non-invasive innovations with everyday accessibility, empowering individuals to take charge of their health anytime, anywhere.
For enquiries, clinical demonstrations, or partnership opportunities, please contact:
Ai Mediq Asia
Phone: +65 6292 0100
Email: [email protected]
Website: www.aimediqasia.com
Contact Info:
Name: Lam Pei Xian
Email: Send Email
Organization: Ai Mediq Asia
Website: https://aimediqasia.com/
Release ID: 89160099
Google
RSS